Tissue Acquisition, Processing, and Pathology (TAPP) Core

组织采集、处理和病理学 (TAPP) 核心

• 批准号: 8566678
• 负责人: MICHAEL D KALOS
• 金额: $ 12.06万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8566678
• 关键词: Anatomy; Antigens; Archives; Biological Assay; Biological Markers; Cell Line; Cessation of life; Chest; Clinical; Clinical Trials; Diagnosis; Enrollment; Goals; Ice; Instruction; Interferon-alpha; Interferons; Malignant Neoplasms; Neoplasm Antibodies; Operative Surgical Procedures; Pathologic; Pathologist; Pathology; Pathology processes; Patients; Process; Role; Sampling; Serological; Serum; Specimen; Specimen Handling; Tissues; Tumor Antigens; Tumor-Derived; immuno-gene therapy; mesothelin; neutralizing antibody; stable cell line; tumor

PROJECT SUMMARY (See instructions): The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.

项目总结（见说明）： 组织采集、处理和病理学核心的目标是： A.审查和分析临床试验患者的病理标本（项目1），包括间皮素水平和潜在的其他肿瘤抗原的表达。 B。处理和存档正在进行和计划进行的临床试验的临床标本（与项目1一起）。 C进行α干扰素、抗腺病毒中和抗体、血清间皮素和抗肿瘤抗体的测定（与项目1一起） D.组织采集（项目1、2和3）。 E.从临床试验受试者和其他手术患者的肿瘤中建立稳定的细胞系（项目1、2和3）。 F.协助免疫组织化学分析 博士由于卡罗尔博士的不幸去世，迈克尔·卡洛斯将担任TAPP核心的主任。Leslie Litzky博士是一名经委员会认证的解剖病理学家，她将专注于目标A，并继续担任指定的参考病理学家，在患者入组临床试验之前确认诊断，并审查肿瘤样本中的间皮素或其他抗原表达。史蒂文·阿尔贝尔达博士 执行经修订的目标C（先前确定的血清学测定）和目标E（细胞系建立）所需的专门知识将有助于这一核心工作。